Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress of Pharmacological Approaches in Parkinson's Disease
Kirsten E. Zeuner, Eva Schäffer, Franziska Hopfner, et al.
Clinical Pharmacology & Therapeutics (2019) Vol. 105, Iss. 5, pp. 1106-1120
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

The future of stem cell therapies for Parkinson disease
Malin Parmar, Shane Grealish, Claire Henchcliffe
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 2, pp. 103-115
Closed Access | Times Cited: 262
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects
Max Borsche, Sandro L. Pereira, Christine Klein, et al.
Journal of Parkinson s Disease (2020) Vol. 11, Iss. 1, pp. 45-60
Open Access | Times Cited: 189
Alzheimer's and Parkinson's disease therapies in the clinic
Puja Chopade, Neha Chopade, Zongmin Zhao, et al.
Bioengineering & Translational Medicine (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 96
Mitochondrial dysfunction in neurodegenerative disorders
Madelyn Klemmensen, Seth H. Borrowman, Colin Pearce, et al.
Neurotherapeutics (2023) Vol. 21, Iss. 1, pp. e00292-e00292
Open Access | Times Cited: 72
Probiotics for Parkinson’s Disease
Parisa Gazerani
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 17, pp. 4121-4121
Open Access | Times Cited: 130
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Franziska Richter, Miloš Stanojlović, Christopher Käufer, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 1, pp. 97-116
Open Access | Times Cited: 23
A 3D disease and regeneration model of peripheral nervous system–on–a–chip
Sujin Hyung, Byungjun Lee, Jiho Kim, et al.
Science Advances (2021) Vol. 7, Iss. 5
Open Access | Times Cited: 44
Effects of Transcranial Direct Current Stimulation on Potential P300-Related Events and Alpha and Beta EEG Band Rhythms in Parkinson's Disease
Rosa Angela Fabio, Rossella Suriano, Antonio Gangemi
Journal of Integrative Neuroscience (2024) Vol. 23, Iss. 2, pp. 25-25
Open Access | Times Cited: 7
Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and α-synuclein fibrils
Ahmed A. Elbatrawy, Taiwo A. Ademoye, Heba Alnakhala, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 100, pp. 117613-117613
Open Access | Times Cited: 6
The Potential of the Cyclotide Scaffold for Drug Development
Julio A. Camarero, Maria Jose Campbell
Biomedicines (2019) Vol. 7, Iss. 2, pp. 31-31
Open Access | Times Cited: 53
Plasma MicroRNA as a novel diagnostic
Rafał Szelenberger, Michał Kacprzak, Joanna Saluk, et al.
Clinica Chimica Acta (2019) Vol. 499, pp. 98-107
Closed Access | Times Cited: 49
Microglia and Parkinson's disease: footprints to pathology
Ekaterina Lazdon, Nofar Stolero, Dan Frenkel
Journal of Neural Transmission (2020) Vol. 127, Iss. 2, pp. 149-158
Closed Access | Times Cited: 49
Genotype-driven therapeutic developments in Parkinson’s disease
Jannik Prasuhn, Norbert Brüggemann
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 33
Piperine-Coated Gold Nanoparticles Alleviate Paraquat-Induced Neurotoxicity in Drosophila melanogaster
Saurabh Srivastav, Bibin G. Anand, Mahino Fatima, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 22, pp. 3772-3785
Closed Access | Times Cited: 36
Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter
Roxine Staats, Thomas C. T. Michaels, Patrick Flagmeier, et al.
Communications Chemistry (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 36
Using the Cyclotide Scaffold for Targeting Biomolecular Interactions in Drug Development
Binu Jacob, Alicia Vogelaar, Enrique Cadenas, et al.
Molecules (2022) Vol. 27, Iss. 19, pp. 6430-6430
Open Access | Times Cited: 20
The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife
Alexander Kilzheimer, Thomas Hentrich, Simone Burkhardt, et al.
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 33
Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease
Asya Ozkızılcık, Aruna Sharma, José Vicente Lafuente, et al.
Progress in brain research (2019), pp. e7-e7
Closed Access | Times Cited: 29
Parkinson’s Disease, Parkinsonisms, and Mitochondria: the Role of Nuclear and Mitochondrial DNA
Andrea Legati, Daniele Ghezzi
Current Neurology and Neuroscience Reports (2023) Vol. 23, Iss. 4, pp. 131-147
Closed Access | Times Cited: 9
Microvascular blood-brain barrier alterations in isolated brain capillaries of mice over-expressing alpha-synuclein (Thy1-aSyn line 61)
Kristina Lau, Lisa T. Porschen, Franziska Richter, et al.
Neurobiology of Disease (2023) Vol. 187, pp. 106298-106298
Open Access | Times Cited: 8
Risk of Parkinson disease associated with pesticide exposure and protection by probiotics
Neelu Kanwar Rajawat, Kanika Bhardwaj, Nupur Mathur
Materials Today Proceedings (2022) Vol. 69, pp. A1-A11
Closed Access | Times Cited: 10
Clinical symptoms, underlying pathogenesis, and the prospect of tailored therapies have all benefited from genetic discoveries in Parkinson's disease
Moataz Dowaidar
(2021)
Open Access | Times Cited: 14
Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease
Hend Jarras, Mélanie Bourque, A Poirier, et al.
Journal of Neuroendocrinology (2019) Vol. 32, Iss. 1
Closed Access | Times Cited: 15
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1615-1615
Open Access | Times Cited: 10
Factors Associated with Medication Beliefs in Patients with Parkinson’s Disease: A Cross-Sectional Study
Sung Reul Kim, Ji Young Kim, Hye Young Kim, et al.
Journal of Movement Disorders (2021) Vol. 14, Iss. 2, pp. 133-143
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top